Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 May;15(5):465-72.
doi: 10.1038/ni.2866. Epub 2014 Apr 6.

Protein kinase C-η controls CTLA-4-mediated regulatory T cell function

Affiliations

Protein kinase C-η controls CTLA-4-mediated regulatory T cell function

Kok-Fai Kong et al. Nat Immunol. 2014 May.

Abstract

Regulatory T (Treg) cells, which maintain immune homeostasis and self-tolerance, form an immunological synapse (IS) with antigen-presenting cells (APCs). However, signaling events at the Treg cell IS remain unknown. Here we show that the kinase PKC-η associated with CTLA-4 and was recruited to the Treg cell IS. PKC-η-deficient Treg cells displayed defective suppressive activity, including suppression of tumor immunity but not of autoimmune colitis. Phosphoproteomic and biochemical analysis revealed an association between CTLA-4-PKC-η and the GIT2-αPIX-PAK complex, an IS-localized focal adhesion complex. Defective activation of this complex in PKC-η-deficient Treg cells was associated with reduced depletion of CD86 from APCs by Treg cells. These results reveal a CTLA-4-PKC-η signaling axis required for contact-dependent suppression and implicate this pathway as a potential cancer immunotherapy target.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interests.

Figures

Figure 1
Figure 1
IS recruitment and CTLA-4 interaction of PKC-η in Treg cells. (a) Immunoblot analysis of T hybridoma cells left unstimulated (-) or stimulated (+) with anti-CD3 plus CD86-Fc for 5 min. CTLA-4 IPs (left and center lanes) or whole cell lysates (WCL) were immunoblotted with the indicated Abs. Arrowheads mark the two PKC-η species. (b) Immunoblot analysis of IPs (left and center lanes) or WCL (right lane) from T hybridoma cells stimulated with anti-CD3 plus CD86-Fc for 5 min. CTLA-4 IPs were left untreated (-) or treated with alkaline phosphatase (AP; +) prior to immunoblotting. (c) Immunoblot analysis of cytosol or nuclear fractions from sorted CD4+CD62L+GFP- (naïve) and CD4+GFP+ (Treg) cells (2 × 106 each) from wild-type FIG mice. Data in (a-c) are representative of at least four experiments. (d) Confocal imaging of PKC-η (top row) or PKC-θ (bottom row) and TCRβ localization in in vitro differentiated iTreg cells from AND TCR-Tg Rag2−/− mice, which were retrovirally transduced with eGFP-tagged mouse PKC-θ or PKC-η 1 d after anti-CD3 and -CD28 stimulation. Sorted GFP+ T cells (~90% FoxP3+ by intracellular staining; not shown) obtained on d 4 and stimulated for 5-10 min by conjugation with MCC-pulsed LPS-stimulated B cells were fixed and analyzed. eGFP-tagged PKC, TCR and nuclear DAPI staining are shown in green, red and blue, respectively. Images are representative of at least 100 cells collected from three independent experiments.
Figure 2
Figure 2
Development of Foxp3+ Treg cells is independent of PKC-η. (a-d) Cell counts (Log10) of CD4+Foxp3+ cells from thymi (a), spleens (b), peripheral lymph nodes (pLN; c) and mesenteric lymph nodes (mLN; d) of 8-12 week-old wild-type or Prkch−/− mice determined by intracellular Foxp3 staining. Each data point represents a single mouse. ns, non significant; *P < 0.05. (e-j) Mean fluorescence intensity (MFI) of Foxp3 (e), TCRβ (f), CTLA-4 (g), CD25 (h), GITR (i) and CD44 (j) expression determined on gated CD4+Foxp3+-cells from wild-type or Prkch−/− mice. (k) IL-10 production (measured by ELISA) by CD4+GFP+ Treg cells from wild-type and Prkch−/− FIG mice, which were stimulated with plate-bound anti-CD3 mAb and CD86-Fc in the presence of IL-2 overnight. For description of FIG mice, see Fig. 3 and the corresponding text.
Figure 3
Figure 3
Contact-dependent suppression by Treg cells depends on PKC-η. (a) In vitro suppression assay measuring the proliferation of CellTrace Violet-labeled naïve B6 CD4+CD25- Teff cells cocultured in the absence (1:0) or presence of Foxp3+ Treg cells from wild-type or Prkch−/−FIG mice at the indicated Teff/Treg cell ratios, and stimulated with anti-CD3 mAb and splenic DCs for 3 d. Percentages of CellTrace Violet-diluting Teff cells were calculated (left panel). The three right panels show representative FACS dot plots of dye-diluting Teff cells cultured with Treg cells at a 1:1 ratio. Data are representative of at least five independent experiments. (b-d) In vivo homeostatic proliferation assay showing the number (Log10) of B6.SJL CD45.1+ naïve T cells recovered from spleens (b), pLN (c) or mLN (d) of recipient Rag1−/− mice 7 d after i.v. transfer of naïve cells (2 × 106) in the absence (none) or presence of FACS-sorted CD4+GFP+ Treg cells (.5 × 106) from FIG or Prkch−/−-FIG mice. Each data point represents a single mouse. (e) Sequential measurements of B16-F10 melanoma growth in groups of Rag1-/- mice (n ≥ 5), which received CD25-depleted B6 splenic cells (1.5 × 107; a source of Teff cells) without or with 0.5 × 106 CD4+GFP+ Treg cells from wild-type or Prkch−/− FIG mice, and were inoculated one day later with tumor cells (2 × 105). Tumor diameters along two perpendicular axes were measured 2-3 times/week. *P < 0.05; **P < 0.01; ***P < 0.001. This experiment is representative of at least three independent experiments.
Figure 4
Figure 4. Cytokine production and serum antibody levels of WT vs. Prkch−/− mice
(a-d) Cytokine expression in culture supernatants of WT or Prkch−/− FACS-sorted CD44hi T cells, which were stimulated with anti-CD3 plus -CD28 mAbs for 24 h and assayed by an ELISA for levels of IL-2 (a), IFNγ (b), IL-4 (c) and IL-17A (d). (e-g) Serum levels of IgE (e), anti-double stranded DNA (f) or anti-histone (g) antibodies in 8-12 week-old wild-type and Prkch−/− mice determined by an ELISA. Each data point represents a single mouse from two pooled experiments. *P < 0.01 **P < 0.001; ***P < 0.0001.
Figure 5
Figure 5
Mapping and biological significance of the CTLA-4-PKC-η interaction sites. (a) Immunoblot analysis of CTLA-4 IPs or WCL from JTAg cells, which were cotransfected with the indicated PKC-η vectors plus wild-type CTLA-4 and stimulated as in Fig. 1a. IgH, heavy chain of the precipitating antibody. Schematic representation of human PKC-η and its phosphorylation sites is shown on top. Data are representative of at leas five independent experiments. (b-d) In vivo homeostatic proliferation assay performed as described in Fig. 3b-d showing the number (Log10) of B6.SJL CD45.1+ naïve T cells, which were recovered from spleens (b), pLN (c) or mLN (d) of recipient Rag1−/− mice 10 d post i.v. transfer of naive cells (2 × 106) in the absence (vector) or presence of FACS-sorted rCD2+CD4+GFP+ Treg cells (.5 × 106). Treg cells were derived from Prkch−/− BM mouse chimeras reconstituted with wild-type PKC-η or a CTLA-4 non-interacting PKC-η-S28A, S32A using retroviral pMIG-IRES-rCD2 vector. Each data point represents a single mouse. ns, non significant; *P < 0.05; **P < 0.01; ***P < 0.001. (e) Immunoblot analysis of CTLA-4 IPs or WCL from JTAg cells cotransfected with the indicated CTLA-4 vectors plus wild-type PKC-η, and processed as in (a). Schematic representation of mouse CTLA-4 is shown on top.
Figure 6
Figure 6
CTLA-4-PKC-η recruits GIT-PIX-PAK complex and modulates Treg cell-APC interaction. (a) Immunoblot analysis of cytosolic (C) and nuclear (N) fractions of FACS-sorted wild-type or Prkch−/− FIG CD4+GFP+ Treg cells, which were stimulated with anti-CD3ε plus -CTLA-4 mAbs for 5 min. (b) Immunoblot analysis of CTLA-4 IPs or WCL of FACS-sorted GFP+ Treg cells derived from FIG mice and left unstimulated (-) or stimulated (+) with ani-CD3 plus anti-CTLA-4 antibodies for 5 min. (c) Expression of phospho-PAK and total PAK2 in lysates of CD4+GFP+ Treg cells from wild-type or Prkch−/− FIG mice determined by immunoblotting with the corresponding antibodies. (d) Conjugation assay measuring formation of cell doublets between FACS-sorted CD4+GFP+ wild-type or Prkch−/− FIG Treg and CellTrace Violet-labeled splenic DCs at different times during a 3 d coculture period in the presence of anti-CD3 mAb and IL-2. Percentages of GFP+ and Violet+ double-positive doublets are shown. *P < 0.05; **P <0.001. (e) CD86 depletion from APCs cocultured in the absence (circles) or presence of FACS-sorted CD4+GFP+ wild-type (squares) or Prkch−/− (triangles) FIG Treg cells. A first set of CD45.2+ splenic DCs was cultured for 9 h in the presence of anti-CD3 mAb and IL-2 prior to the addition of a second set of CD45.1+ splenic DCs. The geometric mean fluorescence intensity of CD86 was enumerated on gated CD11c+ Annexin V CD45.2+ and CD11c+ Annexin V CD45.1+ cells, respectively. The t1/2 values of CD86 decay curves were calculated using the GraphPad Prism™ program. This experiment is representative of three independent experiments. ns, non significant; *P < 0.05.

Comment in

  • New inhibitory signaling by CTLA-4.
    Wülfing C, Tunbridge HM, Wraith DC. Wülfing C, et al. Nat Immunol. 2014 May;15(5):408-9. doi: 10.1038/ni.2870. Nat Immunol. 2014. PMID: 24747703 No abstract available.

References

    1. Bennett CL, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet. 2001;27:20–21. - PubMed
    1. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4:330–336. - PubMed
    1. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299:1057–1061. - PubMed
    1. Zanin-Zhorov A, et al. Protein kinase C-theta mediates negative feedback on regulatory T cell function. Science. 2010;328:372–376. - PMC - PubMed
    1. Collins AV, et al. The interaction properties of costimulatory molecules revisited. Immunity. 2002;17:201–210. - PubMed

Publication types